Why the study?
Does prior anthracycline-based chemotherapy increase imaging biomarkers of interstitial fibrosis (myocardial T1 and ECV) in cancer survivors?
Does prior anthracycline-based chemotherapy increase imaging biomarkers of interstitial fibrosis (myocardial T1 and ECV) in cancer survivors?
Myocardial T1 and ECV are elevated in cancer survivors three years after anthracycline therapy, indicating interstitial fibrosis independent of other cardiovascular comorbidities.
Answers are grounded in this paper and cite their sources.
May signal need for fibrosis surveillance in survivors; hypothesis-generating without outcome linkage.
Three years after anthracycline-based chemotherapy, elevations in myocardial T1 and ECV occur independent of underlying cancer or cardiovascular comorbidities, suggesting that imaging biomarkers of interstitial fibrosis in cancer survivors are related to prior receipt of a potentially cardiotoxic cancer treatment regimen.
No takes yet. Share an insight, caveat, or question.
Jordan et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: